Regarding the ICU population, the above-mentioned ENVIN-HELICS registry showed a trend towards increased SM resistance to TMP/SMX during the last two years (2022–2023) compared with the pre-pandemic period (2018) (6.2% and 13.5% vs. 0%, respectively), similar to tigecycline (60% and 80% vs. 0%), in contrast to levofloxacin that has remained the same or even decreased (13.65 and 13.3% vs. 15.38%, respectively).
← all excerpts
<i>Stenotrophomonas maltophilia</i>: The Landscape in Critically Ill Patients and Optimising Management Approaches.
1
—
—